Key result
FPR2 agonist BMS-986235 prevents cardiac muscle loss in Duchenne muscular dystrophy mice by resolving inflammation.
Why the study?
The common mouse model of DMD does not manifest cardiac deficits until late adulthood, limiting understanding and therapeutic approaches for pediatric-onset cardiac pathology.
Does the FPR2 agonist BMS-986235 prevent fibrotic degeneration and resolve cardiac inflammation in a juvenile D2-mdx mouse model of Duchenne muscular dystrophy?
Does the FPR2 agonist BMS-986235 prevent fibrotic degeneration and resolve cardiac inflammation in a juvenile D2-mdx mouse model of Duchenne muscular dystrophy?
Pro-resolution therapy with an FPR2 agonist prevents juvenile-onset cardiac muscle loss and resolves chronic inflammation in a severe mouse model of Duchenne muscular dystrophy.
D2-mdx mice enable juvenile DMD cardiomyopathy modeling; leaves open translation to pediatric patients pending validation.
Absence of dystrophin protein causes cardiac dysfunction in patients with Duchenne muscular dystrophy (DMD). Unlike boys with DMD, the common mouse model of DMD (B10-mdx) does not manifest cardiac deficits until late adulthood. This has limited our understanding of the mechanism and therapeutic approaches to target the pediatric onset of cardiac pathology in DMD. Here we show that the mdx mouse model on the DBA/2 J genetic background (D2-mdx) displays juvenile-onset cardiac degeneration. Molecular and histological analysis revealed that cardiac damage in this model is linked to increased leukocyte chemotactic signaling and an inability to resolve inflammation. These deficiencies result in chronic inflammation and fibrotic conversion of the extracellular matrix (ECM) in the juvenile D2-mdx heart. To address these pathologies, we tested the utility of pro-resolution therapy to clear chronic cardiac inflammation. Use of an N-formyl peptide receptor (FPR) agonist helped physiologically resolve inflammation and mitigate the downstream events that lead to fibrotic degeneration of cardiomyocytes, preventing juvenile onset cardiac muscle loss. These results establish the utility of D2-mdx model to study events associated with pediatric-onset cardiac damage and demonstrates pro-resolution therapy as an alternate to anti-inflammatory therapy for treating degenerative cardiac pathology that leads to cardiomyopathy in DMD.
No takes yet. Share an insight, caveat, or question.
Novak et al. (2025) studied Duchenne muscular dystrophy. BMS-986235 vs. Saline was evaluated on Cardiac damage and fibrotic degeneration. Treatment with the FPR2 agonist BMS-986235 resolved inflammation and mitigated fibrotic degeneration of cardiomyocytes, preventing juvenile-onset cardiac muscle loss in a mouse model of Duchenne muscular dystrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: